GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment ...Middle East

YONGIN, South Korea, Nov. 25, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA). GC Biopharma and Novel Pharma...

Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment )

Also on site :

• Food Network star Anne Burrell dies aged 55 leaving Worst Cooks in America fans devastated after show absence
• EU state pledges funds to help aspirant counter ‘Russian threats’
• Downtown Lincolnton on lockdown after 'credible threat,' police say no active shooter